Hemogenyx Pharmaceuticals (LSE:HEMO) has secured £118,632 in new funding following the exercise of warrants covering 50,841 ordinary shares, with conversion prices ranging from 180p to 350p per share. The newly issued shares are set to be admitted to the FCA’s Official List and begin trading on the London Stock Exchange’s Main Market, bringing the company’s total issued share capital and voting rights to 6,425,429 shares.
After admission, shareholders should reference the updated share count when assessing disclosure requirements under FCA transparency regulations. While the capital raise represents a relatively small equity issuance, it modestly enhances the company’s financial position and may help support continued development of its clinical-stage pipeline, though it results in slight dilution for existing investors.
Hemogenyx’s outlook remains primarily constrained by weak financial fundamentals, including the absence of revenue, ongoing operating losses and continued cash burn, alongside elevated balance-sheet risk linked to lower equity levels and higher leverage. Technical indicators show strong recent momentum, partially offsetting concerns, although overbought signals introduce potential short-term volatility. Valuation support remains limited due to a negative price-to-earnings ratio and the lack of dividend income.
More about HemoGenyx Pharmaceuticals Plc
HemoGenyx Pharmaceuticals plc is a London-based clinical-stage biopharmaceutical company listed on the LSE under the ticker HEMO. Operating through U.S. subsidiaries in New York City, the group develops innovative medicines, therapeutic candidates and platform technologies aimed at treating blood disorders and autoimmune diseases, targeting areas with significant unmet medical need.
Leave a Reply